Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
Publication date: Available online 15 March 2019Source: The Lancet HIVAuthor(s): Boris Julg, Lynda Dee, Jintanat Ananworanich, Dan H Barouch, Katharine Bar, Marina Caskey, Donn J Colby, Liza Dawson, Krista L Dong, Karine Dubé, Joseph Eron, John Frater, Rajesh T Gandhi, Romas Geleziunas, Philip Goulder, George J Hanna, Richard Jefferys, Rowena Johnston, Daniel Kuritzkes, Jonathan Z LiSummaryAnalytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of n...
Source: The Lancet HIV - March 17, 2019 Category: Infectious Diseases Source Type: research

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
Publication date: Available online 15 March 2019Source: The Lancet HIVAuthor(s): Frances H Priddy, David J M Lewis, Huub C Gelderblom, Hana Hassanin, Claire Streatfield, Celia LaBranche, Jonathan Hare, Josephine H Cox, Len Dally, Daryl Bendel, David Montefiori, Eddy Sayeed, Jim Ackland, Jill Gilmour, Bruce C Schnepp, J Fraser Wright, Philip JohnsonSummaryBackgroundA preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV. We assessed safety and tol...
Source: The Lancet HIV - March 17, 2019 Category: Infectious Diseases Source Type: research

Delivery of anti-HIV bNAbs by viral vectors
Publication date: Available online 15 March 2019Source: The Lancet HIVAuthor(s): Marina Caskey (Source: The Lancet HIV)
Source: The Lancet HIV - March 17, 2019 Category: Infectious Diseases Source Type: research

Extended-release opioid antagonists and HIV treatment
Publication date: Available online 14 March 2019Source: The Lancet HIVAuthor(s): Joshua D Lee, Nikolaj Kunoe (Source: The Lancet HIV)
Source: The Lancet HIV - March 16, 2019 Category: Infectious Diseases Source Type: research

Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial
Publication date: Available online 14 March 2019Source: The Lancet HIVAuthor(s): Evgeny Krupitsky, Elena Blokhina, Edwin Zvartau, Elena Verbitskaya, Dmitri Lioznov, Tatiana Yaroslavtseva, Vladimir Palatkin, Marina Vetrova, Natalia Bushara, Andrei Burakov, Dmitri Masalov, Olga Mamontova, Daniel Langleben, Sabrina Poole, Robert Gross, George WoodySummaryBackgroundUntreated opioid addiction in people with HIV is associated with poor HIV treatment outcomes. Slow-release, long-acting, implantable naltrexone might improve these outcomes. Here, we present results of a study aimed to test this hypothesis.MethodsWe did a 48 week do...
Source: The Lancet HIV - March 16, 2019 Category: Infectious Diseases Source Type: research

Metrics and benchmarks for HIV transition
Publication date: March 2019Source: The Lancet HIV, Volume 6, Issue 3Author(s): Peter D Ghys, Mead Over, Timothy B Hallett, Mary Mahy, Peter Godfrey-Faussett (Source: The Lancet HIV)
Source: The Lancet HIV - March 6, 2019 Category: Infectious Diseases Source Type: research

Metrics and benchmarks for HIV transition – Authors' reply
Publication date: March 2019Source: The Lancet HIV, Volume 6, Issue 3Author(s): Abhishek Pandey, Meagan C Fitzpatrick, Alison P Galvani (Source: The Lancet HIV)
Source: The Lancet HIV - March 6, 2019 Category: Infectious Diseases Source Type: research

Haiti's complex history with HIV, and recent successes
Publication date: March 2019Source: The Lancet HIV, Volume 6, Issue 3Author(s): Joe Parkin Daniels (Source: The Lancet HIV)
Source: The Lancet HIV - March 6, 2019 Category: Infectious Diseases Source Type: research

GHESKIO: adapting to challenges in Haiti since the early 1980s
Publication date: March 2019Source: The Lancet HIV, Volume 6, Issue 3Author(s): Joe Parkin Daniels (Source: The Lancet HIV)
Source: The Lancet HIV - March 6, 2019 Category: Infectious Diseases Source Type: research

Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
Publication date: March 2019Source: The Lancet HIV, Volume 6, Issue 3Author(s): Max R O'Donnell, Nesri Padayatchi, Amrita Daftary, Catherine Orrell, Kelly E Dooley, K Rivet Amico, Gerald FriedlandSummaryBedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with WHO recommendations, in South Africa and other low-income and middle-income settings, antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine with separate compa...
Source: The Lancet HIV - March 6, 2019 Category: Infectious Diseases Source Type: research

Non-Hodgkin lymphoma in people with HIV
Publication date: Available online 27 February 2019Source: The Lancet HIVAuthor(s): David M Aboulafia (Source: The Lancet HIV)
Source: The Lancet HIV - February 28, 2019 Category: Infectious Diseases Source Type: research

Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Publication date: Available online 27 February 2019Source: The Lancet HIVAuthor(s): Raúl U Hernández-Ramírez, Li Qin, Haiqun Lin, Wendy Leyden, Romain S Neugebauer, Keri N Althoff, Chad J Achenbach, Nancy A Hessol, Gypsyamber D'Souza, Kelly A Gebo, M John Gill, Surbhi Grover, Michael A Horberg, Jun Li, W Christopher Mathews, Angel M Mayor, Lesley S Park, Charles S Rabkin, Kate Salters, Amy C JusticeSummaryBackgroundResearch is needed to better understand relations between immunosuppression and HIV viraemia and risk for non-Hodgkin lymphoma, a common cancer in people living with HIV. We aimed to identif...
Source: The Lancet HIV - February 28, 2019 Category: Infectious Diseases Source Type: research

Youth at risk of HIV: the overlooked US HIV prevention crisis
Publication date: Available online 27 February 2019Source: The Lancet HIVAuthor(s): Vincent Guilamo-Ramos, Marco Thimm-Kaiser, Adam Benzekri, Donna Futterman (Source: The Lancet HIV)
Source: The Lancet HIV - February 28, 2019 Category: Infectious Diseases Source Type: research

Optimising HIV antiretrovirals for mothers and infants
Publication date: Available online 24 February 2019Source: The Lancet HIVAuthor(s): Kathleen M Powis, George K Siberry (Source: The Lancet HIV)
Source: The Lancet HIV - February 25, 2019 Category: Infectious Diseases Source Type: research

Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial
Publication date: Available online 24 February 2019Source: The Lancet HIVAuthor(s): Stéphane Blanche, Thorkild Tylleskär, Marianne Peries, Chipepo Kankasa, Ingunn Engebretsen, Nicolas Meda, James K Tumwine, Mandisa Singata-Madliki, Mwiya Mwiya, Philippe Van de Perre, Nicolas Nagot, ANRS 12174 Trial GroupSummaryBackgroundThe tolerance of antiretroviral drugs in infants must be carefully evaluated. In previous studies of children with HIV type 1 (HIV-1) less weight gain was observed in children given lopinavir–ritonavir-based combinations than those given nevirapine. We aimed to compare the effects of lopin...
Source: The Lancet HIV - February 25, 2019 Category: Infectious Diseases Source Type: research

Promoting sexual health and awareness—African style
Publication date: Available online 22 February 2019Source: The Lancet HIVAuthor(s): Talha Burki (Source: The Lancet HIV)
Source: The Lancet HIV - February 23, 2019 Category: Infectious Diseases Source Type: research

The USA can end its HIV epidemic if it gets the politics right
Publication date: Available online 19 February 2019Source: The Lancet HIVAuthor(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - February 20, 2019 Category: Infectious Diseases Source Type: research

Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study
In this study, we aimed to estimate these parameters in a large cohort of people with HIV in the Netherlands.MethodsIn this retrospective cohort study, we used the Dutch ATHENA cohort to estimate crude, age and sex standardised, and risk period-specific incidences of a first venous thrombotic event in people with HIV aged 18 years or older attending 12 HIV treatment centres in the Netherlands. Crude and standardised incidences were compared with European population-level studies of venous thrombotic events. We used time-updated Cox regression to estimate the risk of a first venous thrombotic event in association with HIV-s...
Source: The Lancet HIV - February 16, 2019 Category: Infectious Diseases Source Type: research

Is HIV a provoking factor for venous thrombotic events?
Publication date: Available online 15 February 2019Source: The Lancet HIVAuthor(s): Line D Rasmussen, Niels Obel (Source: The Lancet HIV)
Source: The Lancet HIV - February 16, 2019 Category: Infectious Diseases Source Type: research

Strategies for engaging men in HIV services
Publication date: Available online 15 February 2019Source: The Lancet HIVAuthor(s): Christopher J ColvinSummaryThe importance of men in the global HIV response is increasingly recognised. In most settings, men are less engaged in HIV services and have worse health outcomes than women. The multiple gender, social, economic, political, and institutional factors behind these patterns are well documented. More recently, researchers have been reporting evidence on strategies aimed at improving the engagement of men in HIV services. Several promising approaches exist, including community-based outreach programmes, gender-transfo...
Source: The Lancet HIV - February 16, 2019 Category: Infectious Diseases Source Type: research

Putting participants at the centre of HIV cure research
Publication date: Available online 13 February 2019Source: The Lancet HIVAuthor(s): Karine Dubé, Liz Barr, David Palm, Brandon Brown, Jeff Taylor (Source: The Lancet HIV)
Source: The Lancet HIV - February 14, 2019 Category: Infectious Diseases Source Type: research

Providers should discuss U=U with all patients living with HIV
Publication date: Available online 13 February 2019Source: The Lancet HIVAuthor(s): Sarah K Calabrese, Kenneth H Mayer (Source: The Lancet HIV)
Source: The Lancet HIV - February 14, 2019 Category: Infectious Diseases Source Type: research

Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study
This study is registered with ClinicalTrials.gov, number NCT03227653.FindingsBetween June 19, 2017, and Dec 14, 2017, 141 children were analysed, of whom 72 (51%) used efavirenz-based cART and 69 (49%) used non-efavirenz-based cART. After controlling for age, sex, and clinical and demographic confounders, we observed lower competence (adjusted mean difference −2·43 [95% CI −4·19 to −0·67], p=0·0071), largely driven by lower school performance scores (adjusted mean difference −0·91 [–1·42 to −0·40], p=0·00055), in the efavirenz group...
Source: The Lancet HIV - February 13, 2019 Category: Infectious Diseases Source Type: research

Should efavirenz be used in children and, if so, how?
Publication date: Available online 12 February 2019Source: The Lancet HIVAuthor(s): Mark F Cotton, Barbara Laughton, Helena Rabie (Source: The Lancet HIV)
Source: The Lancet HIV - February 13, 2019 Category: Infectious Diseases Source Type: research

HIV transmission networks among transgender women in Los Angeles County, CA, USA: a phylogenetic analysis of surveillance data
We examined the possible predictors of clustering with multivariate logistic regression. We characterised the genetically linked partners of transgender women and calculated assortativity (the tendency for people to link to other people with the same attributes) for each transmission risk group.Findings8133 (36·3%) of 22 398 individuals clustered in the network across 1722 molecular transmission clusters. Transgender women who indicated a sexual risk factor clustered at the highest frequency in the network, with 147 (43%) of 345 being linked to at least one other person (adjusted odds ratio [aOR] 2·0, p=0&m...
Source: The Lancet HIV - February 12, 2019 Category: Infectious Diseases Source Type: research

Genetic clusters and transmission in transgender women
Publication date: Available online 11 February 2019Source: The Lancet HIVAuthor(s): Tiago Gräf, Joshua T Herbeck (Source: The Lancet HIV)
Source: The Lancet HIV - February 12, 2019 Category: Infectious Diseases Source Type: research

HIV positive in Africa: where are the women?
Publication date: Available online 10 February 2019Source: The Lancet HIVAuthor(s): Jules Morgan (Source: The Lancet HIV)
Source: The Lancet HIV - February 11, 2019 Category: Infectious Diseases Source Type: research

Matching love and HIV in India
Publication date: Available online 10 February 2019Source: The Lancet HIVAuthor(s): Talha Burki (Source: The Lancet HIV)
Source: The Lancet HIV - February 11, 2019 Category: Infectious Diseases Source Type: research

Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Intira J Collins, Kara Wools-Kaloustian, Ruth Goodall, Colette Smith, Elaine J Abrams, Jihane Ben-Farhat, Suna Balkan, Mary-Ann Davies, Andrew Edmonds, Valériane Leroy, Harriet Nuwagaba-Biribonwoha, Kunjal Patel, Mary E Paul, Jorge Pinto, Pablo Rojo Conejo, Annette Sohn, Russell Van Dyke, Rachel Vreeman, Nicky Maxwell, Venessa TimmermanSummaryBackgroundEstimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV are necessary to inform the need for paediatric second-line formulations. We aime...
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Mexico's fragmented health system as a barrier to HIV care
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Juan G Sierra-Madero, Pablo F Belaunzaran-Zamudio, Brenda Crabtree-Ramírez, Carlos Magis-Rodriguez (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Fionnuala Finnerty, Yusef Azad, Chloe Orkin (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Aiming to end San Francisco's HIV epidemic
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Tony Kirby (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

San Francisco AIDS Foundation
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Tony Kirby (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Barriers to paediatric switching to second-line ART
Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Stephen J Kerr, Thanyawee Puthanakit (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Point-of-care assays for early infant diagnosis in Zimbabwe
Publication date: Available online 5 February 2019Source: The Lancet HIVAuthor(s): Sarah J Girdwood, Brooke E Nichols (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study
Publication date: Available online 5 February 2019Source: The Lancet HIVAuthor(s): Simone C Frank, Jennifer Cohn, Lorna Dunning, Emma Sacks, Rochelle P Walensky, Sushant Mukherjee, Caitlin M Dugdale, Esther Turunga, Kenneth A Freedberg, Andrea L CiaranelloSummaryBackgroundNew point-of-care (POC) assays for early infant HIV diagnosis are costlier than conventional total nucleic acid assays, but could increase access to testing, shorten time to results, and expedite initiation of antiretroviral therapy. We aimed to assess the clinical benefits and cost-effectiveness of incorporating these POC assays into early infant diagnos...
Source: The Lancet HIV - February 6, 2019 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2018; 5: e553–59
Publication date: Available online 25 January 2019Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 26, 2019 Category: Infectious Diseases Source Type: research

For the greatest impact, end caps on PrEP access now
Publication date: Available online 24 January 2019Source: The Lancet HIVAuthor(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - January 25, 2019 Category: Infectious Diseases Source Type: research

Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes.MethodsWe included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or ...
Source: The Lancet HIV - January 23, 2019 Category: Infectious Diseases Source Type: research

How do we preserve health among adults living with HIV?
Publication date: Available online 22 January 2019Source: The Lancet HIVAuthor(s): Line D Rasmussen, Niels Obel (Source: The Lancet HIV)
Source: The Lancet HIV - January 23, 2019 Category: Infectious Diseases Source Type: research

Global PrEP roll-out: recommendations for programmatic success
Publication date: Available online 16 January 2019Source: The Lancet HIVAuthor(s): K Rivet Amico, Linda-Gail BekkerSummaryPre-exposure prophylaxis (PrEP) is being adopted and rolled out in diverse regions, communities, and groups. Although it has been shown to be effective, in some settings PrEP roll-out has lagged, in part due to flawed messaging. Lessons can be learned and principles applied from marketing to highlight the potential pitfalls of current roll-out strategies focused on selective and siloed service provision. After exploration of the way PrEP is promoted in awareness messaging (the sell), marketed to select ...
Source: The Lancet HIV - January 17, 2019 Category: Infectious Diseases Source Type: research

The effect of incentives on HIV research must be studied
Publication date: Available online 16 January 2019Source: The Lancet HIVAuthor(s): Brandon Brown, Jerome T Galea (Source: The Lancet HIV)
Source: The Lancet HIV - January 17, 2019 Category: Infectious Diseases Source Type: research

Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial
Publication date: Available online 16 January 2019Source: The Lancet HIVAuthor(s): Harsha Thirumurthy, Alex Ndyabakira, Kara Marson, Devy Emperador, Moses Kamya, Diane Havlir, Dalsone Kwarisiima, Gabriel ChamieSummaryBackgroundViral suppression among HIV-positive individuals is essential for protecting health and preventing HIV transmission. Financial incentives have shown promise in modifying various health behaviours in low-income countries but few studies have assessed whether they can improve HIV treatment outcomes. We aimed to determine the impact of time-limited financial incentives on viral suppression among HIV-pos...
Source: The Lancet HIV - January 17, 2019 Category: Infectious Diseases Source Type: research

Disclosures: Rewriting the Narrative about HIV, Angie Spoto. Stewed Rhubarb Press (2018), 96, £10·99, ISBN: 978-1-910416-10-5
Publication date: Available online 14 January 2019Source: The Lancet HIVAuthor(s): Peter Ranscombe (Source: The Lancet HIV)
Source: The Lancet HIV - January 15, 2019 Category: Infectious Diseases Source Type: research

Progress and challenges in China's free ART programme
Publication date: January 2019Source: The Lancet HIV, Volume 6, Issue 1Author(s): Fujie Zhang, Ye Ma (Source: The Lancet HIV)
Source: The Lancet HIV - January 9, 2019 Category: Infectious Diseases Source Type: research

The past and present violence of Rwanda's HIV epidemic
Publication date: January 2019Source: The Lancet HIV, Volume 6, Issue 1Author(s): Sophie Cousins (Source: The Lancet HIV)
Source: The Lancet HIV - January 9, 2019 Category: Infectious Diseases Source Type: research

Isange One Stop Centre: sanctuary from violence in Rwanda
Publication date: January 2019Source: The Lancet HIV, Volume 6, Issue 1Author(s): Sophie Cousins (Source: The Lancet HIV)
Source: The Lancet HIV - January 9, 2019 Category: Infectious Diseases Source Type: research

HIV prevention cascades: a unifying framework to replicate the successes of treatment cascades
Publication date: January 2019Source: The Lancet HIV, Volume 6, Issue 1Author(s): Robin Schaefer, Simon Gregson, Elizabeth Fearon, Bernadette Hensen, Timothy B Hallett, James R HargreavesSummaryMany countries are off track to meet targets for reduction of new HIV infections. HIV prevention cascades have been proposed to assist in the implementation and monitoring of HIV prevention programmes by identifying gaps in the steps required for effective use of prevention methods, similar to HIV treatment cascades. However, absence of a unifying framework impedes widespread use of prevention cascades. Building on a series of consu...
Source: The Lancet HIV - January 9, 2019 Category: Infectious Diseases Source Type: research

Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities
Publication date: Available online 21 December 2018Source: The Lancet HIVAuthor(s): Chama Mulubwa, Bernadette Hensen, Mwelwa M Phiri, Kwame Shanaube, Albertus J Schaap, Sian Floyd, Comfort R Phiri, Chiti Bwalya, Virginia Bond, Musonda Simwinga, Lawrence Mwenge, Sarah Fidler, Richard Hayes, Alwyn Mwinga, Helen Ayles, HPTN 071 (PopART) Study TeamSummaryBackgroundThe HPTN 071 (PopART) cluster-randomised trial provided door-to-door HIV testing services to a large proportion of individuals residing in 21 intervention communities in Zambia and South Africa from 2014 to 2017 and reached the UNAIDS first 90 target among women in Z...
Source: The Lancet HIV - December 22, 2018 Category: Infectious Diseases Source Type: research

Reaching the 90-90-90 target: lessons from HIV self-testing
Publication date: Available online 21 December 2018Source: The Lancet HIVAuthor(s): Connie Celum, Ruanne Barnabas (Source: The Lancet HIV)
Source: The Lancet HIV - December 22, 2018 Category: Infectious Diseases Source Type: research